SEC Filing Summary: Coeptis Therapeutics Holdings, Inc.
Business Context and Reporting Period
This Form 8-K was filed on August 9, 2024, by Coeptis Therapeutics Holdings, Inc. (COEP), a Delaware corporation. The report addresses a material accounting error requiring the restatement of previously issued financial statements. The filing covers the period from September 30, 2023, through March 31, 2024, and includes registration statements filed in 2023.
Key Financial Metrics and Accounting Error
The filing does not provide specific revenue, profit, or cash flow figures. Instead, it details a classification error regarding note agreements:
- Error Description: Note agreements were incorrectly recorded as "notes receivable" on the consolidated balance sheet.
- Correct Classification: These items should have been recorded as "subscription receivables."
- Current Status: As of August 12, 2024, the balance of the subscription receivables has been satisfied.
- Affected Documents: The error impacts the unaudited 10-Q for Q3 2023, the audited 10-K for FY 2023, the unaudited 10-Q for Q1 2024, and specific S-1 Registration Statements.
Material Changes and Restatement
The Audit Committee determined that the previously issued financial statements for the "Affected Periods" can no longer be relied upon. The company expects to file applicable restated financial statements as soon as practicable. This restatement is a direct result of an internal review and consultation with the independent auditor, Turner, Stone & Company, L.L.P.
Outlook, Risks, and Management Commentary
Management has discussed the matter with the Audit Committee and independent auditors. The company previously identified weaknesses in disclosure controls and procedures, leading to the hiring of a full-time Chief Financial Officer in 2023 to improve processes. The filing highlights significant risks associated with the restatement, including:
- Substantial costs and diversion of personnel resources to address the restatement.
- Potential litigation or regulatory action.
- Reputational damage and potential impact on the value of common stock.
- Delays in the completion of interim reviews and audits.
- Uncertainty regarding the remediation of material weaknesses in internal controls.
Investor Verification Checklist
- Verify the timeline for the filing of the restated 10-Q and 10-K documents.
- Confirm the specific financial impact of reclassifying notes receivable to subscription receivables on the balance sheet.
- Monitor for any updates regarding the effectiveness of internal controls over financial reporting.
- Check for any regulatory inquiries or litigation arising from the accounting error.
- Review the status of the subscription receivables to ensure they remain satisfied.